3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
2
Renal Insufficiency
1
Interventions
Dexamethasone
10
Bortezomib
7
Lenalidomide
4
isatuximab
3
Calcium Dobesilate
3
pomalidomide
2
Thalidomide
2
Gemcitabine
2
Cyclophosphamide
2
vinflunine
1
melflufen
1
glucarpidase
1
gallium 68 PSMA-11
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
daratumumab
1
carfilzomib
1
auricularum
1
Tablets
1
Ranitidine
1
Pluvicto
1
L-melphalanyl-p-L-fluorophenylalanine ethyl ester
1
Eplerenone
1
Doxorubicin
1
Diphenhydramine
1
Carboplatin
1
Bendamustine Hydrochloride
1
BHQ880
1
Acetaminophen
1
ARQ 197
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Renal Insufficiency
×
melflufen
×
Clear all
NCT03639610
2023-03-10
BRIDGE
Oncopeptides AB
Phase 2
Terminated
35 enrolled
33 charts